| Document |
Document Title |
|
WO2005117538A9 |
This invention provides methods, compositions and articles of manufacture for inhibiting binding between Aß protein and ABAD in cells. Uses of this invention include, for example, treating Alzheimer's disease; reducing free radical gene...
|
|
WO/2006/008386A1 |
The invention relates to biomaterials comprising a carrier material to which surface spherical particles are covalently linked, wherein said spherical particles are formed by polymer chains containing approximately from 30 to 10000 monom...
|
|
WO/2006/002472A1 |
A method of immobilising a target molecule on a substrate, which comprises exposing the target molecule to the substrate in the presence of a metal complex, wherein the target molecule is an unmodified target molecule, and wherein the me...
|
|
WO/2006/004067A1 |
An efficient and economically advantageous process for producing a protein A-like protein. In the production of a protein A-like protein utilizing the technology of genetic manipulation, use is made of a host, such as Escherichia coli or...
|
|
WO/2006/001798A1 |
A general chiral column with a multiple proline-based chiral stationary phase.
|
|
WO/2005/120564A2 |
Methods of enhancing antigenic presentation or increasing immunogenicity of a polypeptide accomplished by modifying the three dimensional structure of a polypeptide.
|
|
WO/2005/121181A1 |
Multi-drop tree branching polyethylene glycol-oligopeptides and active derivates of formula II, in which, R1 is a center molecule, containing multiple active groups, on these groups linear PEG is derivated and therefor forming finally mu...
|
|
WO/2005/118614A1 |
Compositions and methods for the treatment of neuropathic pain are provided. Compositions of the invention may comprise proteins with a zinc-finger domain fused to a regulatory domain that is capable of either activating or repressing th...
|
|
WO/2005/116081A2 |
The invention provides compositions and methods for storage of biomolecules. The biomolecules are stored via absorption to a substrate. Absorbed biomolecules can be eluted or recovered from the substrate at a future time, and optionally ...
|
|
WO/2005/116085A1 |
A protein-cyclodextrin derivative obtained by the reaction of a reactive cyclodextrin and a protein. The invention includes protein-cyclodextrin derivatives having the general formula (III); wherein (a) and R´-NH is the residue of a hyd...
|
|
WO/2005/116255A2 |
Materials and methods are provided to prepare therapeutic conjugates for the treatment of proliferative diseases. The therapeutic conjugates of the invention comprise a targeting moiety conjugated to a therapeutic moiety. The therapeutic...
|
|
WO/2005/107491A2 |
Methods, compositions, and kits related to the use of multi-ligand affinity chromatography are described. The methods include those related to identification of glycoprotein panels for analyzing and diagnosisng disease.
|
|
WO/2005/105151A1 |
The invention relates to long lasting thymosin 1 derivatives, methods of manufacturing the salt thereof used as the medicament and the use thereof. The long lasting thymosin derivative is a thymosin derivative linked to polyethylene glyc...
|
|
WO/2005/103259A1 |
The invention provides polypeptides, nucleic acids, antibodies, compositions, vaccines, microarrays and uses thereof for the prevention, treatment of SARS and SARS-CoV infection. The invention further provides uses of the above-noted p...
|
|
WO2005019831B1 |
The present invention relates generally to methods for reducing the complexity of a sample. More specifically, the present invention relates to proteomics, the measurement of the protein levels in biological samples, and analysis of prot...
|
|
WO/2005/096706A2 |
The present invention provides a new immunogen, a novel antibody having high specificity for MTA (5'-deoxy-5'-methylthioadenosine), methods of treatment and medicaments prepared using said antibody, and sensitive assays for measuring spe...
|
|
WO/2005/095962A1 |
The invention aims at providing a method for immobilizing polypeptides strongly and specifically; a detection method and a purification method for polypeptides; and a solid support for the methods. A method for immobilizing polypeptides ...
|
|
WO/2005/093417A1 |
Methods, compositions and kits are disclosed. Enzyme conjugates of Formula I may be employed in assays for the determination of an amphetamine and/or a methamphetamine. Immunogenic conjugates of Formula I may be employed to prepare antib...
|
|
WO/2005/088307A1 |
Immunoassays for the detection of everolimus are provided. Compounds for producing antibodies for everolimus, as well as antibodies produced therefrom, are also provided.
|
|
WO/2005/077421A1 |
The invention related to a method of preparing pegylated interferon alpha 1b covalently bounding to actived polyethylene glycol. To achieve the modified interferon alpha 1b protein, where the histidine and lysine on the protein surface w...
|
|
WO/2005/070968A1 |
It is intended to provide a method of immobilizing a protein on a solid phase characterized by comprising bringing the protein into contact with the solid phase having hydrophobic surface in the presence of a lower alcohol, a halogenocar...
|
|
WO/2005/070969A1 |
It is intended to provide a method of immobilizing a protein on a solid phase characterized by comprising bringing the protein into contact with the solid phase having a hydrophobic surface in the coexistence of a lower alcohol with a ha...
|
|
WO/2005/071387A1 |
ADAM 12 expression and activity are up regulated in patients that have cancers of epithelial origin, such as breast cancer, colon cancer, prostate cancer, liver cancer, bladder cancer, pancreatic cancer, ovarian cancer, cervical cancer, ...
|
|
WO/2005/070960A1 |
The present invention relates to a method of modifying a polypeptide, which yields a modifed polypeptide, suitable for site-specific coupling, for example, as a targeting ligand, as well as modified human EGF and fragments thereof, suita...
|
|
WO/2005/068087A2 |
The invention relates to methods for coating objects with hydrophobins. Provided is a method for providing the surface of an object with a hydrophobin coating, comprising contacting at least a part of an object with a hydrophobin-contain...
|
|
WO/2005/062959A2 |
Isolated T cell receptors having binding specificity for a particular class of MHC polypeptide in complex with autoantigens are provided. Methods of producing the isolated T cell receptors and methods of using the isolated T cell recepto...
|
|
WO/2005/064336A1 |
The invention provides a novel class of reactive fluorescent agents that are based on a pyrene sulfonic acid nucleus. The agents are readily incorporated into conjugates with other species by reacting the reactive group with a group of c...
|
|
WO/2005/061482A1 |
Methods, compositions and kits are disclosed. Enzyme conjugates of Formula (I) are employed in assays for the determination of an methylenedioxyamphetamine, a methylene-dioxyethamphetamine, and/or a methylenedioxymethamphetamine. Immunog...
|
|
WO/2005/058865A2 |
Methods, compositions and kits are disclosed. The methods are directed to determining the presence of entactogen analytes such as, for example, 3,4-methylenedioxamphetamine (MDA), 3,4-methylenedioxy-methamphetamine (MDMA), 3,4-methylened...
|
|
WO/2005/058948A1 |
The present invention pertains to the protection against malaria. More particularly, the invention is based on the characterization of a novel liver and sporozoite-stage P. falciparum antigen, referred to as LSA-5. This antigen is highly...
|
|
WO/2005/059100A2 |
A method of treating amyloidoses by administering an effective amount of a cystatin C composition or by increasing protein expression of cystatin C. A method of preventing fibril formation or deposition by administering an effective amou...
|
|
WO/2005/058864A1 |
Methods, compositions and kits are disclosed. The methods are directed to determining the presence of entactogen analytes such as, for example, 3,4methylenedioxyamphetamine (MDA)3,4-methylenedioxy-methamphetamine (MDMA), 3,4-methylened...
|
|
WO/2005/057207A1 |
The present invention provides a method of forming an ion of formula (I) comprising the steps of: (i) reacting a compound of the formula (IIa); with a biopolymer, BP, having at least one group capable of reacting with M to form a covalen...
|
|
WO/2005/055957A2 |
A chimeric, carboxy-terminal truncated hepatitis B virus nucleocapsid (HBc) protein is disclosed that contains an immunogen for inducing the production of antibodies to the influenza M2 protein. An immunogenic influenza sequence in two t...
|
|
WO/2005/057462A1 |
A method of producing a binding surface for a target molecule having a functional binding site, which method comprises: (i) identifying within the target molecule an anchor site which is remote from the functional binding site; (ii) gene...
|
|
WO/2005/056569A2 |
Recombinant materials for the production of β integrin protein characteristic of Manduca sexta are useful for screening pesticides for this moth.
|
|
WO/2005/053617A2 |
In various embodiments, a collagen product is provided that is derived from an animal, the collagen product comprises precipitated collagen that is substantially pure. In various embodiments, the collagen is obtained from a marine animal...
|
|
WO/2005/051976A2 |
Provided are enzyme-catalyzed methods, and related products and kits, for efficiently linking a molecule to a protein or peptide and conjugates generated therefrom. An enzyme often utilized has transamidase activity, such as a sortase or...
|
|
WO2005013889A9 |
The application identifies novel fragments of alpha-synuclein in patients with Lewy Body Disease (LBD) and transgenic animal models thereof. These diseases are characterized by aggregations of alpha-synuclein. The fragments have a trunca...
|
|
WO/2005/046587A2 |
The invention relates to Inter-alpha inhibitor proteins (I&agr Ip). The invention further relates to processes for purification of I&agr Ip compositions and their use for treatment of human diseases such as sepsis and septic shock, rheum...
|
|
WO/2005/045439A1 |
In one embodiment, the present invention provides a detection complex which is useful for detecting a specific analyte of interest in a sample. The complex comprises a detection marker indirectly connected to an analyte binding partner b...
|
|
WO/2005/040338A2 |
Immunogens useful in the production of anti-nicotine antibodies are provided. Anti-nicotine antibodies that immunoreact with the immunogens and nicotine and uses of the immunogens and antibodies in treating nicotine addiction are also pr...
|
|
WO/2005/037852A2 |
A method of trimerizing collagenous molecule monomers comprising the step of contacting a collagen domain and a non-collagenous trimerization domain is provided. In addition, methods of trimerizing heterologous peptides is provided. Trim...
|
|
WO/2005/035585A1 |
A support having affinity for an antibody characterized in that the carboxy end of a protein or a peptide capable of binding to an antibody molecule is immobilized via an amide bond mediated by a linker sequence to an insoluble support h...
|
|
WO/2005/035554A1 |
It is mainly intended to provide a technique relating to dioxin whereby dioxin can be easily detected or quantified by using a substance, which is less expensive and can be easily prepared, and dioxin can be obtained. A dioxin-binding pe...
|
|
WO/2005/033146A1 |
The present invention relates to a microcarrier onto the surface of which a cationic compound has been immobilised via a guanidine group. The microcarrier is capable of attachment of cells, e.g. via charge-based interaction, and is advan...
|
|
WO/2005/033274A2 |
The invention relates to a method of producing a protein of interest, comprising making a non-human transgenic mammal that produces said protein in its milk, obtaining said milk from the non-human transgenic mammal and purifying said pro...
|
|
WO/2005/033267A2 |
The present invention is based on the identification of a predominant ligand of CD8+ T cells that are responsible for type 1 diabetes. That ligand is islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP). Several ...
|
|
WO/2005/033281A2 |
The invention relates to a method of producing a protein of interest, comprising making a non-human transgenic mammal that produces said protein in its milk, obtaining said mild from the non-human transgenic mammal and purifying said pro...
|
|
WO/2005/030979A2 |
Non-fluorescent dyes (i.e., dark quenchers) which can be used to quench the fluorescence of energy donors in bioassays through fluorescence resonance energy transfer (FRET) are described. The dark quenchers can be associated with (e.g., ...
|
